Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s481481 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Ruihua Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Phthalazines, Piperazines. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trial Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
- Clinical Department, CSPC Zhongqi Pharmaceutical Technology (SJZ) Co., LTD., Shijiazhuang, Hebei Province, People's Republic of China.
ORCID-Profile: Nini Guo
Zitieren
APA
Dong, R., Chen, J., Guo, N., Yang, Y., Wu, J., Wang, X., Song, Y., & Zhang, X. (2024). Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s481481
Vancouver
Dong R, Chen J, Guo N, Yang Y, Wu J, Wang X, et al. Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s481481
BibTeX
@article{Dong2024,
author = {Dong, Ruihua and Chen, Jingcheng and Guo, Nini and Yang, Yingying and Wu, Jingxuan and Wang, Xiaoru and Song, Yuqin and Zhang, Xueyuan},
title = {Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s481481}
}
EUVIMED